Research progress of multi-target HDAC inhibitors blocking the BRD4-LIFR-JAK1-STAT3 signaling pathway in the treatment of cancer.
Jia S, Jia Y, Liang S, Wu L.
Bioorg Med Chem · review; journal article · DOI 10.1016/j.bmc.2024.117827 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
29 träffarFunctional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity.
Miao Y, Virtanen A, Zmajkovic J, Hilpert M, Skoda RC, Silvennoinen O, Haikarainen T.
J Med Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1021/acs.jmedchem.4c00197Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors.
Brauer NR, Kempen AL, Hernandez D, Sintim HO.
Eur J Med Chem · research-article; review; journal article · DOI 10.1016/j.ejmech.2024.116540Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency.
Pan Y, Hou H, Zhou B, Gao J, Gao F.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2023.115879Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer.
Zhao C, Zhang Y, Zhang J, Li S, Liu M, Geng Y, Liu F, Chai Q, Meng H, Li M, Li J, Zheng Y, Zhang Y.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c01242Synthesis and clinical application of small-molecule inhibitors of Janus kinase.
Zhang JY, Sun JF, Nie P, Herdewijn P, Wang YT.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2023.115848Emerging opportunities to treat idiopathic pulmonary fibrosis: Design, discovery, and optimizations of small-molecule drugs targeting fibrogenic pathways.
Luo W, Gu Y, Fu S, Wang J, Zhang J, Wang Y.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2023.115762A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.
Sutherland JJ, Yonchev D, Fekete A, Urban L.
Nat Commun · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41467-023-40064-9Deciphering the multifunctional role of dual leucine zipper kinase (DLK) and its therapeutic potential in disease.
Bu H, Li Z, Lu Y, Zhuang Z, Zhen Y, Zhang L.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2023.115404Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers.
Qiu Q, Chi F, Zhou D, Xie Z, Liu Y, Wu H, Yin Z, Shi W, Qian H.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c00036Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.
Shen P, Wang Y, Jia X, Xu P, Qin L, Feng X, Li Z, Qiu Z.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2022.114551Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells.
Dominici C, Sgarioto N, Yu Z, Sesma-Sanz L, Masson JY, Richard S, Raynal NJ.
Clin Epigenetics · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s13148-021-01037-1Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof.
Davis RR, Li B, Yun SY, Chan A, Nareddy P, Gunawan S, Ayaz M, Lawrence HR, Reuther GW, Lawrence NJ, Schönbrunn E.
J Med Chem · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.jmedchem.0c01952Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Raghuvanshi R, Bharate SB.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.0c01467Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.
Xie Z, Yang X, Duan Y, Han J, Liao C.
J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.0c01511Development and Therapeutic Potential of NUAKs Inhibitors.
Faisal M, Kim JH, Yoo KH, Roh EJ, Hong SS, Lee SH.
J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.0c00533New drug approvals for 2019: Synthesis and clinical applications.
Yuan S, Yu B, Liu HM.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2020.112667Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.
Xu P, Shen P, Yu B, Xu X, Ge R, Cheng X, Chen Q, Bian J, Li Z, Wang J.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2020.112155Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.
Yang T, Hu M, Qi W, Yang Z, Tang M, He J, Chen Y, Bai P, Yuan X, Zhang C, Liu K, Lu Y, Xiang M, Chen L.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.9b01348Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances.
Bryan MC, Rajapaksa NS.
J Med Chem · review; journal article · DOI 10.1021/acs.jmedchem.8b00667In depth analysis of kinase cross screening data to identify chemical starting points for inhibition of the Nek family of kinases.
Wells CI, Kapadia NR, Couñago RM, Drewry DH.
Medchemcomm · review-article; review; journal article · DOI 10.1039/c7md00510eThe target landscape of clinical kinase drugs.
Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C, Zecha J, Reiter K, Qiao H, Helm D, Koch H, Schoof M, Canevari G, Casale E, Depaolini SR, Feuchtinger A, Wu Z, Schmidt T, Rueckert L, Becker W, Huenges J, Garz AK, Gohlke BO, Zolg DP, Kayser G, Vooder T, Preissner R, Hahne H, Tõnisson N, Kramer K, Götze K, Bassermann F, Schlegl J, Ehrlich HC, Aiche S, Walch A, Greif PA, Schneider S, Felder ER, Ruland J, Médard G, Jeremias I, Spiekermann K, Kuster B.
Science · research support, non-u.s. gov't; research-article; journal article · DOI 10.1126/science.aan4368Non-kinase targets of protein kinase inhibitors.
Munoz L.
Nat Rev Drug Discov · review; journal article · DOI 10.1038/nrd.2016.266Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective.
Carlino L, Rastelli G.
J Med Chem · review; journal article · DOI 10.1021/acs.jmedchem.6b00438Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
Siegel MB, Liu SQ, Davare MA, Spurgeon SE, Loriaux MM, Druker BJ, Scott EC, Tyner JW.
Oncotarget · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.18632/oncotarget.4214Comprehensive analysis of kinase inhibitor selectivity.
Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP.
Nat Biotechnol · journal article · DOI 10.1038/nbt.1990SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.
Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, Tan YC, Madan B, Amalini C, Loh YK, Ong LC, William AD, Lee A, Poulsen A, Jayaraman R, Ong KH, Ethirajulu K, Dymock BW, Wood JW.
Leukemia · journal article · DOI 10.1038/leu.2011.148Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
Malerich JP, Lam JS, Hart B, Fine RM, Klebansky B, Tanga MJ, D'Andrea A.
Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2010.10.026CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A.
Leukemia · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1038/leu.2009.50